Eris Lifesciences to buy balance 30 percent stake in Swiss Parenterals for Rs 423 crore

Written By :  Ruchika Sharma
Published On 2025-11-26 08:22 GMT   |   Update On 2025-11-26 08:22 GMT
Advertisement

Mumbai: Eris Lifesciences Limited has announced that its Board of Directors has approved the acquisition of the balance 30 percent stake in Swiss Parenterals Limited for Rs 423.3 crore, making swiss a wholly owned subsidiary. Currently Eris holds a 70 percent stake in Swiss.

The proposed transaction will be effected as a share swap, i.e. through a preferential issuance of Eris equity shares to the seller Naishadh Shah, who is also a Director of Swiss and consequently a related party of Swiss, thereby making him a Top-10 shareholder of Eris and an integral part of Eris’ senior management team with long-term alignment.

Advertisement

The acquisition aims to strengthen operational synergies, improve cost efficiencies, and give Eris full control over Swiss.

The proposed transaction is expected to complete tentatively prior to March 31, 2026.

Commenting on the acquisition, Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd, said, ”On behalf of the shareholders of Eris, I am delighted to welcome Naishadh Shah to the community of Erisians. I am also happy to share that we propose to designate him as the Managing Director of Swiss Parenterals. FY27 promises to be a breakout year for our international business and Naishadh’s continued leadership and stewardship will be pivotal to its growth.”

Commenting on the acquisition, Naishadh Shah, Wholetime Director of Swiss Parenterals Ltd, said, ”It is truly exciting to get aligned with Eris as a long-term shareholder and senior management. The Eris platform with its manufacturing capabilities in Ahmedabad and Bhopal, combined with the existing Swiss facilities, will significantly augment our value proposition to our global clientele. I look forward to the next leg of this growth journey.”

With an annual branded formulations revenue of Rs 3,000+ Cr as per AWACS, Eris has built a diversified presence across specialties and super-specialties such as Diabetes, Cardiovascular, Dermatology, Nephrology, Neurology, Women’s Health, Oncology and Critical Care.
Established in 2007, Eris manufactures a wide range of prescription products across several dosage forms including Oral Solids, Oral Liquids, Softgels, Ointments, Sprays & Gels, Sterile Injectables and Biologics in its 6 manufacturing facilities, and markets these products across India through a network of 5,000 stockists and 5,00,000+ retail pharmacies.
Eris’ revenue and operating profit have grown 2.6x in the last 5 years, with FY25 revenue of Rs 2,894 Cr. The company has diversified its presence across geographies, technologies and therapeutic areas with an investment of Rs 4,000 Cr over the last 3 years.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News